Low Gleason score prostatic adenocarcinomas are no longer viable entities

被引:23
作者
Berney, D. M. [1 ]
机构
[1] Barts & London Queen Mary Univ Sch Med & Dent, Dept Cellular Pathol, St Bartholomews Hosp, London, England
关键词
adenocarcinoma; Gleason; prostate;
D O I
10.1111/j.1365-2559.2007.02596.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Gleason scoring is the most powerful predictor of the behaviour of prostatic adenocarcinoma. It was devised more than 30 years ago and is used by pathologists worldwide. However, advances in immunochemistry and the understanding of the biological potential of some tumours have made the diagnosis of tumours of grades 1 and 2, and hence low score (2-4), a rarity. It is suggested that Gleason score 2(1 + 1) tumours, if they do exist, are so rare and so benign that they are a redundant entity and should not be identified as a malignancy. Similar problems revolve around the diagnosis of Gleason score 4(2 + 2) tumours and the criteria for their diagnosis are difficult to evaluate and revolve around reference to the score 2(1 + 1) lesion. The continued presence of low-grade tumours in the Gleason grading system leads to diagnostic confusion, potential error and, more importantly, confusion for patients diagnosed with score 6(3 + 3) tumours. I suggest that Gleason grade 1 (and therefore scores of 2 and 3) should be removed from the Gleason grading system. Gleason grade 2 (and therefore score 4 and 5) tumours require serious re-evaluation if they are to remain clinically useful diagnoses.
引用
收藏
页码:683 / 690
页数:8
相关论文
共 47 条
[1]   Prostate cancer and the Will Rogers phenomenon [J].
Albertsen, PC ;
Hanley, JA ;
Barrows, GH ;
Penson, DF ;
Kowalczyk, PDH ;
Sanders, MM ;
Fine, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1248-1253
[2]   20-year outcomes following conservative management of clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Fine, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101
[3]   Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists [J].
Allsbrook, WC ;
Mangold, KA ;
Johnson, MH ;
Lane, RB ;
Lane, CG ;
Amin, MB ;
Bostwick, DG ;
Humphrey, PA ;
Jones, EC ;
Reuter, VE ;
Sakr, W ;
Sesterhenn, IA ;
Troncoso, P ;
Wheeler, TM ;
Epstein, JI .
HUMAN PATHOLOGY, 2001, 32 (01) :74-80
[4]   Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologists [J].
Allsbrook, WC ;
Mangold, KA ;
Johnson, MH ;
Lane, RB ;
Lane, CG ;
Epstein, JI .
HUMAN PATHOLOGY, 2001, 32 (01) :81-88
[5]  
Amin M.B., 2004, GLEASON GRADING PROS
[6]  
[Anonymous], UROLOGIC PATHOLOGY
[7]  
[Anonymous], 2004, PATHOLOGY GENETICS T
[8]   Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy [J].
Blute, ML ;
Bergstralh, EJ ;
Iocca, A ;
Scherer, B ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (01) :119-125
[9]  
BOCKING A, 1980, PATHOL RES PRACT, V168, P115
[10]  
BOCKING A, 1982, CANCER, V50, P288, DOI 10.1002/1097-0142(19820715)50:2<288::AID-CNCR2820500220>3.0.CO